Clinical stage gene editing company Precision BioSciences (Nasdaq:DTIL) announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).
This designation is intended to facilitate development and expedite review of therapies for serious conditions with unmet medical need.
PBGENE-DMD is a first-in-class gene editing therapy using a single AAV to deliver two ARCUS proteins designed to permanently edit the dystrophin gene, producing near full-length functional dystrophin. The therapy targets mutations in exons 45-55, representing up to 60% of boys with DMD. Preclinical studies demonstrated durable functional improvements across key muscles, including cardiac, diaphragm, and skeletal tissue, and successfully edited muscle satellite cells critical for long-term efficacy.
Precision BioSciences believes the Fast Track designation underscores both the potential of PBGENE-DMD and the urgent need for new treatment options for DMD.
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera